CAS: 68475-42-3; 6,7-Dichloro-5,10-Dihydroimidazo[2,1-B]Quinazolin-2(3H)-One

该化合物是一种合成化合物,主要用作减少血栓血病等基本条件下高血清计数的药物,它具有选择性地抑制巨型甲状腺细胞分化和小板生产的作用,从而降低与高血小板水平相关的血栓事件的风险; 甲状腺素的化学结构包括一个助长其药理活动的基,它通常通过口服施用,在肝脏中代谢,其影响取决于剂量; 常见副作用可能包括头痛,头晕和胃肠紊乱; 甲状腺素的动作机制涉及抑制环烷基单磷酸盐(cAMP),导致高浓度的碳酸酯,这反过来会影响板生产; 由于它针对巨型甲状腺素的特定行动,安甲状腺素与其他抗糖素制剂不同,因此它在管理某些血病病病方面是一种宝贵的选择; 与任何药物一样,它对于监测病人的潜在不利影响和与其他药物的相互作用至关重要.

结构式图片

相似化合物

3010286-98-0 1092352-99-2 108857-18-7

欧盟法规

C&L通报

上下游产品

CAS号146374-56-3 (2-氰基亚氨基-5,6-二氯... | CAS号70381-75-8 5,6-二氯-3,4-二氢-2... | CAS号58579-51-4 盐酸阿那格雷

合成工艺路线路线简述

    Anagrelide Hemiformate置于水体系中,用 乙醇 作为反应溶剂,化学反应 3.0H,以99%的收率获得产物氯喳味唑酮
    参考文献: Process For Making Anagrelide[fr] Procédé De Préparation D'Anagrélide
    标题: Process For Making Anagrelide[fr] Procédé De Préparation D'Anagrélide
    摘要:该发明涉及一种制备和纯化药用活性化合物阿格雷利特(分子式为(1))的方法.该方法基于将阿格雷利特或其酸盐转化为阿格雷利特的甲酸盐,特别是阿格雷利特半甲酸盐.

    海关参考信息

    专利信息


    专利号:US-12383499-B2
    优先权日:2018-01-01
    标题:Scale up synthesis of silicasome nanocarriers
    发明人:NEL ANDRE E; MENG HUAN; LIU XIANGSHENG
    权利人:UNIV CALIFORNIA
    摘要:In order to facilitate the approval and commercialization of silicasome drug delivery systems (e.g. irinotecan silicasomes) it is necessary to scale up synthesis of the drug-loaded silicasomes. In this regard, it was discovered that the synthesis protocols used for laboratory synthesis of drug-loaded silicasomes (e.g., 500 mg/batch) do not scale to large scale silicasome production, because the resulting products were too heterogeneous for use as pharmaceuticals. Accordingly, new methods are provided herein that effectively afford the large-scale production of mesoporous silica nanoparticles (MSNPs) and lipid bilayer coated MSNPs (silicasomes).

    专利号:US-10925977-B2
    优先权日:2006-10-05
    标 题 :Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
    发明人:YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S
    权利人:YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S; CEIL POINT LLC; UNIV TEXAS
    摘要:Novel methods of synthesis of chelator-targeting ligand conjugates, compositions comprising such conjugates, and therapeutic and diagnostic applications of such conjugates are disclosed. The compositions include chelator-targeting ligand conjugates optionally chelated to one or more metal ions. Methods of synthesizing these compositions in high purity are also presented. Also disclosed are methods of imaging, treating and diagnosing disease in a subject using these novel compositions, such as methods of imaging a tumor within a subject and methods of diagnosing myocardial ischemia.

    专利号:US-12391691-B2
    优先权日:2018-11-16
    标题:Synthesis of key intermediate of KRAS G12C inhibitor compound
    发明人:PARSONS ANDREW THOMAS; COCHRAN BRIAN MCNEIL; POWAZINIK IV WILLIAM; CAPORINI MARC ANTHONY
    权利人:AMGEN INC
    摘要:The present invention relates to an improved, efficient, scalable process to prepare intermediate compounds, such as compound 5M, having the structure n nuseful for the synthesis of compounds that target KRAS G12C mutations, such as

    专利号:US-2025206736-A1
    优先权日:2019-11-14
    标题 :Synthesis of kras g12c inhibitor compound
    发明人:CORBETT MICHAEL THOMAS; CAILLE SEBASTIEN
    权利人:AMGEN INC
    摘要:The present disclosure relates to an improved, efficient, scalable process to prepare intermediate compounds, such as 2-isopropyl-4-methylpyridin-3-amine, useful for the synthesis of compounds, such as Compound 9, for the treatment of KRAS G12C mutated cancers.

    专利号:US-9315483-B2
    优先权日:2007-09-13
    标题 :Synthesis of deuterated catechols and benzo[D][1,3]dioxoles and derivatives thereof
    发明人:JONES ANDREW D; ZELLE ROBERT E; SILVERMAN I ROBERT
    权利人:CONCERT PHARMACEUTICALS INC
    摘要:The present invention provides a convenient and efficient process for the synthesis of d 2 -benzo[d][1,3]dioxoles.

    专利号:US-8828984-B2
    优先权日:2012-11-19
    标题:Gold(III) complexes containing N-heterocyclic carbene ligand, synthesis, and their applications in cancer treatment and thiol detection
    发明人:CHE CHI MING; ZOU TAOTAO
    权利人:UNIV HONG KONG; UNIV HONG KONG
    摘要:Provided herein is a method of synthesis of Au(III)-NHC complexes, a pharmaceutical composition comprises thereof. Also provided herein are the methods for the treatment and prevention of cancer/tumor in patients in need thereof by the administration of the Au(III)-NHC complexes. Also provided is method of detecting thiol in a biological system. The Au(III)-NHC complexes possess anticancer activity such as the induction of cell death, inhibition of cellular proliferation, inhibition of thioredoxin reductase activity, and inhibition of tumor growth in vivo.
    常州航宇医药技术开发有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.czyys.com
    电话: 86-519-88802789 13961196887👤
    📞常州航宇医药技术开发有限公司 ⚠️参考联系方式

    销售电话:86-519-88802789 13961196887
    邮箱:sales@czyys.com
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    第 1 / 1 页
    现货

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Buxhofer-Ausch V, Steurer M, Sormann S, Schloegl E, Schimetta W, Gisslinger B, Schalling M, Krauth MT, Thiele J, Ruckser R, Gastl G, Gisslinger H. Impact of white blood cells on thrombotic risk in patients with optimised platelet count in essential thrombocythemia. Eur J Haematol. 2018 Mar 30. doi: 10.1111/ejh.13070. [Epub ahead of print] pii: bcr-2017-220723. doi: 10.1136/bcr-2017-220723. doi: 10.1097/MD.0000000000008735. Review.
    4: Birgegård G, Besses C, Griesshammer M, Gugliotta L, Harrison CN, Hamdani M, Wu J, Achenbach H, Kiladjian JJ. Treatment of essential thrombocythemia in Europe: a prospective long-term observational study of 3649 high-risk patients in the Evaluation of Anagrelide Efficacy and Long-term Safety study. Haematologica. 2018 Jan;103(1):51-60. doi: 10.3324/haematol.2017.174672. Epub 2017 Oct 27.
    5: Speirs C, Williams JJL, Riches K, Salt IP, Palmer TM. Linking energy sensing to suppression of JAK-STAT signalling: A potential route for repurposing AMPK activators? Pharmacol Res. 2018 Feb;128:88-100. doi: 10.1016/j.phrs.2017.10.001. Epub 2017 Oct 13. Review. doi: 10.1016/j.jogoh.2017.08.005. Epub 2017 Sep 1. doi: 10.1038/leu.2017.230. Epub 2017 Jul 24.

    合成参考文献


    摘要:S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (2021) DOI:10.1021/acsenvironau.1c00008. List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知